WRF
TEVA icon

Waddell & Reed Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Waddell & Reed Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,053,800
Closed -$36K – 629
2016
Q3 		$36K Buy
+1,053,800
New +$55M ﹤0.01% 588

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Waddell & Reed Financial's TEVA Position: Q4 2017 in Review

Waddell & Reed Financial sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,930,671 shares — an estimated $34M sold.

Waddell & Reed Financial first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $1.19B in Q4 2015. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Waddell & Reed Financial reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Waddell & Reed Financial sold 1,930,671 Teva Pharmaceuticals shares in Q4 2017, an estimated $34M.
  • Waddell & Reed Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Waddell & Reed Financial's Teva Pharmaceuticals position peaked at $1.19B in Q4 2015.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Waddell & Reed Financial's 13F filing for Q4 2017, filed 14 Feb 2018.